288 filings
Page 4 of 15
8-K
gswi6xkii243 p1
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
DEFA14A
dtnx14v 4r
29 Apr 21
Additional proxy soliciting materials
5:09pm
DEFA14A
tfylnrhzmiq
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
x3hp gvuz2qydrsym
19 Apr 21
Preliminary proxy
5:28pm
8-K
vcob313g60p6l hv6
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
2afzw70wdag0i67z
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
3xhvt4dg ui7
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
1cikocn ifogswg1db32
1 Oct 20
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
4:38pm
8-K
8phel4350ug58g2z
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
424B5
qsvlv67
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
r16scbx01w13mdani
10 Sep 20
Termination of a Material Definitive Agreement
4:02pm
8-K
qwl eaekmvf7rj5
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
21kj9f5kvdx teup1kb
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
9m8il2j
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
S-8
xn9o0zza344z7mgs
10 Aug 20
Registration of securities for employees
4:16pm
8-K
2cm hz33cmp
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am